Tomoko Funazo

Tomoko Funazo

Auto-generated profile, based on publicly available information

Tomoko Funazo

Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
TTTakahiro TSUJI
Takahiro TSUJI
HOHiroaki Ozasa
Hiroaki Ozasa
WAWataru Aoki
Wataru Aoki
SAShunsuke Aburaya
Shunsuke Aburaya
TFTomoko Yamamoto Funazo
Tomoko Yamamoto Funazo
THToyohiro Hirai
Toyohiro Hirai
Despite the promising clinical efficacy of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in patients with ALK-rearranged lung cancer, some tumor cells survive and eventually relapse, which may be an obstacle to achieving a cure. Limited information is currently available on the mechanisms underlying the initial survival of tumor cells against alectinib. Using patient-derived cell line models, we herein demonstrate that cancer cells survive a treatment with alectinib by activating Yes-associated protein 1 (YAP1), which mediates the expression of the anti-apoptosis factors Mcl-1 and Bcl-xL, and combinatorial inhibition against both YAP1 and ALK provides a longer tumor remission in ALK-rearranged xenografts when compared with alectinib monotherapy. These results suggest that the inhibition of YAP1 is a candidate for combinatorial therapy with ALK inhibitors to achieve complete remission in patients with ALK-rearranged lung cancer.

19 November 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
TFTomoko Yamamoto Funazo
Tomoko Yamamoto Funazo
TNTakashi Nomizo
Takashi Nomizo
HOHiroaki Ozasa
Hiroaki Ozasa
TTTakahiro TSUJI
Takahiro TSUJI
YYYuto Yasuda
Yuto Yasuda
YKYoung Hak Kim
Young Hak Kim
Nivolumab improves the prognosis of non-small cell lung cancer (NSCLC) but can cause immune-related adverse events (irAEs). Reports have indicated longer progression-free survivals (PFSs) in patients with irAEs than in those without irAEs. We reported associations between programmed death ligand-1 (PD-L1) single nucleotide polymorphisms (SNPs) and PFS after nivolumab treatment. We hypothesized that adverse events might be associated with the SNPs of PD-L1. We analyzed data from 111 patients with NSCLC treated with nivolumab. The response rate was 14%, and the median PFS was 68 days. We found patients with the adverse event of low free tetraiodothyronine (fT4) had significantly longer PFSs than those without low fT4 (not reached vs 67 days; hazard ratio [HR], 0.297; P = 0.010). Moreover, median overall survival was longer in patients with low fT4 than those without low fT4 (not reached vs 556 days, HR, 0.139; P = 0.020). Patients with the T allele of rs1411262 (P = 0.0073) and with the A allele of rs822339 (P = 0.0204) developed low fT4. Patients with the T/T genotype had longer PFSs than with those with the C/T and C/C genotypes of rs1411262 (165 vs. 67 days, HR, 1.65; P = 0.040), and those with the A/A genotype had longer PFSs than those with the A/G and G/G genotypes of rs822339 (182 vs. 67 days, HR, 1.76; P = 0.025). In the patients with advanced NSCLC, low fT4 after nivolumab treatment was associated with significantly longer PFSs. The SNPs of PD-L1 may be associated with the adverse events of nivolumab.

11 August 2017 in Molecular and Clinical Oncology
Verified
Journal Article
Open access
PDF file
YYYuto Yasuda
Yuto Yasuda
TNTakashi Nomizo
Takashi Nomizo
HOHiroaki Ozasa
Hiroaki Ozasa
TFTomoko Funazo
Tomoko Funazo
TTTakahiro TSUJI
Takahiro TSUJI
YKYoung-Hoon Kim
Young-Hoon Kim
Lung cancer with preexisting interstitial lung disease (ILD) is difficult to treat due to the risk of acute exacerbation of ILD. Nanoparticle albumin-bound (nab‑) paclitaxel improves the overall response rate and reduces neuropathy more efficiently compared with conventional solvent‑based (sb‑) paclitaxel in patients with advanced non‑small‑cell lung cancer. However, it is not known whether the risk of acute exacerbation of ILD with nab‑paclitaxel is higher compared with that with sb-paclitaxel. Advanced lung cancer patients with ILD treated with nab‑paclitaxel (n=14) or sb‑paclitaxel (n=14) were retrospectively reviewed. Acute exacerbation of ILD developed in 1/14 patients (7.7%) receiving nab‑paclitaxel and 3/14 patients (21.4%) receiving sb‑paclitaxel; the difference was not statistically significant. To the best of our knowledge, this is the first study to compare the incidence of acute exacerbation of ILD with nab‑paclitaxel with that of sb‑paclitaxel in patients with advanced lung cancer with preexisting ILD. The results of the present study support conducting a prospective clinical trial to confirm the clinical benefit of this agent.

5 December 2023 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
TOTatsuya Ogimoto
Tatsuya Ogimoto
HOHiroaki Ozasa
Hiroaki Ozasa
TTTakahiro TSUJI
Takahiro TSUJI
TFTomoko Funazo
Tomoko Funazo
MYMasatoshi Yamazoe
Masatoshi Yamazoe
THToyohiro Hirai
Toyohiro Hirai
EGFR-tyrosine kinase inhibitors (TKI) are the first-line therapies for EGFR mutation–positive lung cancer. EGFR-TKIs have favorable therapeutic effects. However, a large proportion of patients with EGFR mutation–positive lung cancer subsequently relapse. Some cancer cells survive the initial treatment with EGFR-TKIs, and this initial survival may be associated with subsequent recurrence. Therefore, we aimed to overcome the initial survival against EGFR-TKIs. We hypothesized that yes-associated protein 1 (YAP1) is involved in the initial survival against EGFR-TKIs, and we confirmed the combined effect of EGFR-TKIs and a YAP1–TEAD pathway inhibitor. The KTOR27 (EGFR kinase domain duplication) lung cancer cell lines established from a patient with EGFR mutation–positive lung cancer and commercially available PC-9 and HCC827 (EGFR exon 19 deletions) lung cancer cell lines were used. These cells were used to evaluate the in vitro and in vivo effects of VT104, a TEAD inhibitor. In addition, YAP1 involvement was investigated in pathologic specimens. YAP1 was activated by short-term EGFR-TKI treatment in EGFR mutation–positive lung cancer cells. In addition, inhibiting YAP1 function using siRNA increased the sensitivity to EGFR-TKIs. Combination therapy with VT104 and EGFR-TKIs showed better tumor-suppressive effects than EGFR-TKIs alone, in vitro and in vivo. Moreover, the combined effect of VT104 and EGFR-TKIs was observed regardless of the localization status of YAP1 before EGFR-TKI exposure. These results suggest that combination therapy with the TEAD inhibitor and EGFR-TKIs may improve the prognosis of patients with EGFR mutation–positive lung cancer.

7 July 2026 in Nature Communications
Verified
Journal Article
Open access
KHKazutaka Hosoya
Kazutaka Hosoya
HOHiroaki Ozasa
Hiroaki Ozasa
TTTakahiro TSUJI
Takahiro TSUJI
MOMasahiro Oi
Masahiro Oi
YSYusuke Shima
Yusuke Shima
THToyohiro Hirai
Toyohiro Hirai
Brain metastases (BrMs) in non-small cell lung cancer (NSCLC) respond poorly to anti-PD-1 monotherapy, but the underlying immune resistance remains incompletely defined. Here we integrate clinical outcome analyses, paired human tissue profiling and syngeneic mouse models to characterize the BrM immune microenvironment. Clinical analyses suggest improved intracranial disease control with nivolumab plus ipilimumab compared with nivolumab alone. Paired human specimens show that BrMs contain fewer cytotoxic T lymphocytes (CTLs) and tertiary lymphoid structures (TLSs) than primary tumors, defining an immune-excluded phenotype. A syngeneic BrM model recapitulates this phenotype and resists anti-PD-1 monotherapy, whereas combined anti-PD-1 and anti-CTLA-4 blockade suppresses tumor growth and prolongs survival. Single-cell RNA sequencing, flow cytometry and immunofluorescence show increased CTL infiltration and effector function after combination therapy. CD8 + T cell depletion abrogates therapeutic benefit, and combination therapy expands T follicular helper-like cells and induces TLS-like structures. These findings manifest increased adaptive immune response of dual checkpoint blockade in NSCLC BrMs.